Total Payments
$547,565
2024 Payments
$10,442
Companies
88
Transactions
1,744
Medicare Patients
3,220
Medicare Billing
$760,322
Payment Breakdown by Category
Other$333,165 (60.8%)
Travel$110,012 (20.1%)
Consulting$65,089 (11.9%)
Food & Beverage$38,307 (7.0%)
Education$992.48 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $329,600 | 137 | 60.2% |
| Travel and Lodging | $110,012 | 225 | 20.1% |
| Consulting Fee | $65,089 | 32 | 11.9% |
| Food and Beverage | $38,307 | 1,312 | 7.0% |
| Honoraria | $3,000 | 2 | 0.5% |
| Education | $992.48 | 35 | 0.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $565.00 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Ipsen Biopharmaceuticals, Inc | $163,212 | 179 | $0 (2024) |
| Celgene Corporation | $85,353 | 146 | $0 (2024) |
| Amgen Inc. | $83,167 | 170 | $0 (2023) |
| Janssen Biotech, Inc. | $64,971 | 135 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $58,463 | 46 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $21,673 | 121 | $0 (2024) |
| Gilead Sciences, Inc. | $9,357 | 33 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $6,568 | 27 | $0 (2024) |
| Seattle Genetics, Inc. | $6,316 | 17 | $0 (2019) |
| Coherus Biosciences Inc. | $5,779 | 7 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,442 | 239 | Karyopharm Therapeutics Inc. ($2,920) |
| 2023 | $8,837 | 186 | Janssen Biotech, Inc. ($4,178) |
| 2022 | $29,603 | 208 | E.R. Squibb & Sons, L.L.C. ($16,329) |
| 2021 | $16,123 | 157 | Coherus Biosciences Inc. ($5,779) |
| 2020 | $27,362 | 118 | Celgene Corporation ($12,698) |
| 2019 | $115,371 | 211 | Janssen Biotech, Inc. ($43,755) |
| 2018 | $171,171 | 284 | Ipsen Biopharmaceuticals, Inc ($66,904) |
| 2017 | $168,657 | 341 | Ipsen Biopharmaceuticals, Inc ($86,640) |
All Payment Transactions
1,744 individual payment records from CMS Open Payments — Page 1 of 70
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $26.14 | General |
| Category: ONCOLOGY | ||||||
| 12/20/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $23.07 | General |
| Category: Oncology | ||||||
| 12/18/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $31.68 | General |
| Category: Oncology | ||||||
| 12/16/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $28.63 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/11/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $28.95 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $33.35 | General |
| Category: Oncology | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $23.44 | General |
| Category: Oncology | ||||||
| 12/02/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $29.02 | General |
| 11/27/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $21.05 | General |
| Category: ONCOLOGY | ||||||
| 11/25/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $16.55 | General |
| Category: DESMOID TUMORS | ||||||
| 11/21/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $47.42 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $27.17 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $69.54 | General |
| 11/19/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $25.92 | General |
| Category: Hematology | ||||||
| 11/18/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $32.26 | General |
| 11/18/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug), Vitrakvi | Food and Beverage | In-kind items and services | $31.24 | General |
| Category: Oncology | ||||||
| 11/16/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $145.03 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/15/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $14.05 | General |
| Category: Hematology/Oncology | ||||||
| 11/14/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $13.53 | General |
| Category: Oncology | ||||||
| 11/13/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $13.09 | General |
| Category: DESMOID TUMORS | ||||||
| 11/11/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $32.16 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/07/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $10.32 | General |
| Category: Oncology | ||||||
| 11/04/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $23.82 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $15.29 | General |
| 11/01/2024 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | In-kind items and services | $14.47 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 627 | 26,655 | $714,252 | $151,552 |
| 2022 | 16 | 677 | 48,542 | $804,314 | $171,520 |
| 2021 | 19 | 916 | 51,404 | $945,836 | $221,183 |
| 2020 | 20 | 1,000 | 36,011 | $963,779 | $216,067 |
Total Patients
3,220
Total Services
162,612
Medicare Billing
$760,322
Procedure Codes
72
All Medicare Procedures & Services
72 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 15 | 23,400 | $295,196 | $55,397 | 18.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 150 | 341 | $132,787 | $29,067 | 21.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 77 | 133 | $76,245 | $18,680 | 24.5% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 12 | 13 | $72,124 | $15,514 | 21.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 15 | 68 | $28,601 | $6,707 | 23.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 22 | 63 | $22,204 | $5,981 | 26.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 164 | 575 | $13,582 | $4,327 | 31.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 24 | 24 | $16,108 | $4,098 | 25.4% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 15 | 19 | $19,383 | $3,351 | 17.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 22 | 22 | $11,221 | $2,831 | 25.2% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 11 | 72 | $6,631 | $1,554 | 23.4% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 12 | 13 | $4,627 | $1,313 | 28.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 21 | 120 | $6,223 | $1,278 | 20.5% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 11 | 13 | $7,783 | $664.92 | 8.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 25 | 60 | $559.80 | $504.00 | 90.0% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2023 | 14 | 1,700 | $736.00 | $205.56 | 27.9% |
| 82272 | Stool analysis for blood, by peroxidase activity | Office | 2023 | 17 | 19 | $241.11 | $78.85 | 32.7% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2022 | 12 | 34,300 | $431,808 | $86,657 | 20.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 180 | 492 | $190,876 | $44,451 | 23.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 57 | 57 | $38,133 | $9,265 | 24.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 12 | 74 | $31,005 | $8,078 | 26.1% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2022 | 11 | 10,710 | $39,744 | $6,176 | 15.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 184 | 630 | $14,685 | $4,809 | 32.7% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2022 | 17 | 17 | $16,965 | $3,451 | 20.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 32 | 35 | $9,624 | $2,492 | 25.9% |
About William Velasquez, M. D
William Velasquez, M. D is a Medical Oncology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1346201175.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, William Velasquez, M. D has received a total of $547,565 in payments from pharmaceutical and medical device companies, with $10,442 received in 2024. These payments were reported across 1,744 transactions from 88 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($329,600).
As a Medicare-enrolled provider, Velasquez has provided services to 3,220 Medicare beneficiaries, totaling 162,612 services with total Medicare billing of $760,322. Data is available for 4 years (2020–2023), covering 72 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location Houston, TX
- Active Since 03/31/2006
- Last Updated 05/26/2020
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1346201175
Products in Payments
- Onivyde (Drug) $140,291
- DARZALEX (Biological) $117,673
- Revlimid (Drug) $79,374
- Kyprolis (Biological) $65,917
- Pomalyst (Drug) $13,934
- Somatuline Depot (Drug) $8,474
- ONIVYDE (Drug) $8,282
- Kyprolis (Drug) $8,049
- Zydelig (Drug) $5,696
- ADCETRIS (Biological) $5,314
- Non-Covered $3,729
- EMPLICITI (Biological) $3,498
- IMBRUVICA (Drug) $3,166
- Vonjo (Drug) $3,161
- MYLOTARG (Biological) $3,064
- Zevalin (Drug) $3,018
- Somatuline Depot 120mg-.5ml (Drug) $3,000
- XPOVIO (Drug) $2,920
- Cabometyx (Drug) $2,480
- CALQUENCE (Drug) $2,452
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Houston
Roy Herbst, M.d., Phd, M.D., PHD
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Dr. Putao Cen, Md, MD
Medical Oncology — Payments: $817,580
Medical Oncology $817,580
Hagop Kantarjian, Md, MD
Medical Oncology — Payments: $740,835
Medical Oncology $740,835
Dr. Matthew Ellis, Md Phd, MD PHD
Medical Oncology — Payments: $714,994
Medical Oncology $714,994
Eleni Efstathiou, M.d, M.D
Medical Oncology — Payments: $600,908
Medical Oncology $600,908
Srdan Verstovsek, M.d., Phd, M.D., PHD
Medical Oncology — Payments: $577,763
Medical Oncology $577,763